VRTX R&D to Revenue
Vertex Pharmaceuticals · R&D to Revenue
VRTX R&D to Revenue
Latest reported29.81%period ending
VRTX Quarterly R&D/Revenue (0.00% → 29.81%)
Latest values, visible window
High-resolution chart · PNG
VRTX r&d to revenue history
Quarterly. Dates are reporting period ends; fiscal years can differ from calendar years.
| Period ending | R&D to Revenue |
|---|---|
| 29.8089% | |
| 32.1939% | |
| 30.1726% | |
| 33.5522% | |
| 33.0017% | |
| 35.3657% | |
| 34.296% | |
| 31.5993% | |
| 204.7059% | |
| 32.2231% | |
| 53.6879% | |
| 34.697% | |
| 35.9458% | |
| 31.27% | |
| 30.1429% | |
| 27.6314% | |
| 27.3245% | |
| 28.7533% | |
| 33.499% | |
| 24.8846% | |
| 78.4607% | |
| 26.4439% | |
| 28.6631% | |
| 32.0813% | |
| 27.6112% | |
| 29.6037% | |
| 33.9647% | |
| 58.5314% | |
| 40.2734% | |
| 39.5475% | |
| 50.325% | |
| 42.1281% | |
| 44.8752% | |
| 48.4634% | |
| 47.0608% | |
| 78.6881% | |
| 53.1947% | |
| 38.2757% | |
| 54.1637% | |
| 66.5494% | |
| 62.7903% | |
| 64.2735% | |
| 74.2769% | |
| 79.4936% | |
| 134.7925% | |
| 155.657% | |
| 139.3668% | |
| 106.6776% | |
| 162.3887% | |
| 201.74% | |
| 71.0819% | |
| 103.0974% | |
| 71.5865% | |
| 66.4179% | |
| 63.8062% | |
| 59.5707% | |
| 46.9858% | |
| 44.7582% | |
| 33.0951% | |
| 28.679% | |
| 151.0138% | |
| 215.324% | |
| 257.7498% | |
| 716.2597% | |
| 490.4244% | |
| 637.6209% | |
| 399.038% | |
| 529.4386% | |
| 730.8592% | |
| 598.7781% | |
| 440.7363% | |
| 411.174% | |
| 183.1636% | |
| 274.9418% | |
| 226.1923% | |
| 314.4024% | |
| 356.5478% | |
| 192.6726% | |
| 115.7999% | |
| 180.3656% | |
| 306.9703% | |
| 192.3964% | |
| 106.9044% | |
| 175.629% | |
| 183.6484% | |
| 200.7796% | |
| 136.1792% | |
| 181.8622% | |
| 255.9193% | |
| 237.9661% | |
| 431.6484% | |
| 272.6406% | |
| 288.5298% | |
| 234.9374% | |
| 134.3596% | |
| 147.6893% | |
| 109.9598% | |
| 115.5474% | |
| 86.6084% | |
| 94.4213% |